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Abstract
Background: Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein
cholesterol (LDL-C) goals. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and
atorvastatin (20 mg) in high-risk patients with hypercholesterolemia.
Methods: A total of 996 patients with hypercholesterolemia (LDL-C ≥ 3.4 and < 5.7 mmol/L [130 and 220 mg/dL]) and
coronary heart disease (CHD), atherosclerosis, or a CHD-risk equivalent were randomized to once-daily rosuvastatin
10 mg or atorvastatin 20 mg. The primary endpoint was the percentage change from baseline in LDL-C levels at 6 weeks.
Secondary endpoints included LDL-C goal achievement (National Cholesterol Education Program Adult Treatment Panel
III [NCEP ATP III] goal < 100 mg/dL; 2003 European goal < 2.5 mmol/L for patients with atherosclerotic disease, type 2
diabetes, or at high risk of cardiovascular events, as assessed by a Systematic COronary Risk Evaluation (SCORE) risk ≥
5% or 3.0 mmol/L for all other patients), changes in other lipids and lipoproteins, cost-effectiveness, and safety.
Results: Rosuvastatin 10 mg reduced LDL-C levels significantly more than atorvastatin 20 mg at week 6 (44.6% vs. 42.7%,
p < 0.05). Significantly more patients achieved NCEP ATP III and 2003 European LDL-C goals with rosuvastatin 10 mg
compared with atorvastatin 20 mg (68.8% vs. 62.5%, p < 0.05; 68.0% vs. 63.3%, p < 0.05, respectively). High-density
lipoprotein cholesterol was increased significantly with rosuvastatin 10 mg versus atorvastatin 20 mg (6.4% vs. 3.1%, p <
0.001). Lipid ratios and levels of apolipoprotein A-I also improved more with rosuvastatin 10 mg than with atorvastatin
20 mg. The use of rosuvastatin 10 mg was also cost-effective compared with atorvastatin 20 mg in both a US and a UK
setting. Both treatments were well tolerated, with a similar incidence of adverse events (rosuvastatin 10 mg, 27.5%;
atorvastatin 20 mg, 26.1%). No cases of rhabdomyolysis, liver, or renal insufficiency were recorded.
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Conclusion: In high-risk patients with hypercholesterolemia, rosuvastatin 10 mg was more efficacious than atorvastatin
20 mg at reducing LDL-C, enabling LDL-C goal achievement and improving other lipid parameters. Both treatments were
well tolerated.
Background
There is a wealth of evidence suggesting that lowering low-
density lipoprotein cholesterol (LDL-C) reduces the risk
of cardiovascular disease (CVD) [1-4]. Both European and
US guidelines for CVD prevention recommend the use of
3-hydroxy-3-methylgluatryl coenzyme A reductase inhib-
itors (statins) as first-line therapy for dyslipidemia and
specify target LDL-C levels [5,6]. More recently, a National
Cholesterol Education Program (NCEP) report has pro-
posed to lower target levels to even more aggressive LDL-
C goals for very high-risk patients [7].
Despite the proven benefits of LDL-C reduction, lipid
management is suboptimal and many patients fail to
achieve recommended LDL-C goals [8-10]. The most
likely reasons for this are the use of agents with a poor effi-
cacy for LDL-C lowering and suboptimal dose titration. In
high-risk patients with elevated LDL-C, goal attainment is
particularly poor since treatment with higher doses of stat-
ins is often necessary to achieve their target LDL-C levels.
Furthermore, these patients are set more aggressive LDL-C
goals, which are consequently harder to achieve. The most
effective statin at the lowest dose would represent a sim-
ple, effective treatment strategy, enabling more patients to
achieve goals without the need for dose titration.
Rosuvastatin, at a dose of 10 mg, has demonstrated high
efficacy for LDL-C lowering, enabling patients with hyper-
cholesterolemia to achieve their lipid goals [11,12]. In
addition, rosuvastatin has beneficial effects on other com-
ponents of the lipid profile, including high-density lipo-
protein cholesterol (HDL-C) [11,13,14], which is a major,
independent risk factor for CVD[5,6]. Safety data from
several large-scale clinical and pharmacoepidemiologic
studies has shown that the safety of rosuvastatin 10–40
mg was similar to that observed for the other statins stud-
ied and that rosuvastatin demonstrated a favorable bene-
fit-risk profile across this dose range [15-18]. Results from
a recent study by the National Lipid Association (NLA)
also support these findings [19].
The aim of the PULSAR (Prospective study to evaluate the
Use of Low doses of the Statins Atorvastatin and Rosuvas-
tatin, 4522IL/0102) study was to compare the efficacy and
safety of rosuvastatin 10 mg/day and atorvastatin 20 mg/
day for 6 weeks in high-risk patients with hypercholester-
olemia and known coronary heart disease (CHD), athero-
sclerosis or a CHD-risk equivalent. The doses chosen for
the study were generally recommended start doses of
rosuvastatin (10 mg) and atorvastatin (20 mg). PULSAR is
the first, prospective, large-scale, multinational study
designed to compare low doses of rosuvastatin and atorv-




This was a 6-week, open-label, randomized, parallel-
group study conducted in 121 centers in Australia, Fin-
land, France, Italy, Mexico, the Netherlands, and the USA
between November 2003 and August 2004. Patients were
required to discontinue all lipid-lowering therapy before
entering a 6-week dietary lead-in period, during which
they followed the NCEP Adult Treatment Panel (ATP) III
Therapeutic Lifestyle Changes diet [6]. Patients were then
randomized 1:1 to once-daily oral treatment with rosuv-
astatin 10 mg or atorvastatin 20 mg for 6 weeks. Randomi-
zation was conducted by telephone using an interactive
voice recognition system.
The study was performed in accordance with the ethical
principles in the Declaration of Helsinki and was consist-
ent with International Conference of Harmonisation
Good Clinical Practice guidelines and applicable regula-
tory requirements. It was approved by the local institu-
tional review boards of all the participating centers, and
all patients gave written, informed consent before enroll-
ment.
Patients
Men and women aged ≥ 18 years of age with hypercholes-
terolemia and either a history of CHD, clinical evidence of
atherosclerosis or a CHD-risk equivalent (other clinical
form of atherosclerotic disease [peripheral arterial disease,
abdominal aortic aneurysm or symptomatic carotid artery
disease (transient ischemic attacks, stroke of carotid ori-
gin, or > 50% obstruction of a carotid artery)], diabetes
mellitus or ≥ 2 risk factors that confer a 10-year CHD-risk
score > 20%) were eligible for randomization to the study
if the mean of their 2 most recent fasting LDL-C levels was
≥ 3.4 and < 5.7 mmol/L (130 and 220 mg/dL), and the
two measurements were within 15% of each other. Eligi-
ble patients were also required to have fasting triglycerides
(TG) < 4.5 mmol/L (400 mg/dL).
Exclusion criteria included: history of statin-induced
myopathy or a serious hypersensitivity reaction to statins;
p a t i e n ts  c o n s i d e re d  t o  b e  u n s t ab l e  ( e v e n t  w i th i n  8 – 12Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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weeks) after a myocardial infarction (MI), unstable
angina, myocardial revascularization (percutaneous
transluminal coronary angioplasty, coronary artery bypass
graft surgery, or another revascularization procedure) or a
transient ischemic attack or stroke; patients awaiting a
planned myocardial revascularization; severe congestive
heart failure (New York Heart Association class IIIb or IV);
history of malignancy; history of known homozygous
familial hypercholesterolemia; current active liver disease
(alanine aminotransferase [ALT] > 2 × upper limit of nor-
mal [ULN]); unexplained creatine kinase (CK) ≥ 3 × ULN;
serum creatinine > 176 μmol/L (2.0 mg/dL); uncontrolled
hypothyroidism (thyroid-stimulating hormone > 1.5 ×
ULN); a history of alcohol or drug abuse within the last 5
years, and initiation of hormone-replacement therapy or
oral contraceptives within 3 months before enrollment. In
addition, women who were pregnant, breast-feeding or of
child-bearing potential and not using a reliable form of
contraception were excluded.
Disallowed concomitant medications included erythro-
mycin, fluconazole, ketoconazole, and itraconazole,
lipid-modifying drugs, such as niacin, and certain immu-
nosuppressants, such as cyclosporine. Other restrictions
during the study included fasting for 8 hours before each
visit and avoiding alcohol or cigarettes on the morning of
each visit.
Objectives
The primary endpoint was the percentage change from
baseline (at randomization, week 0) in LDL-C levels after
6 weeks of treatment. Secondary efficacy endpoints
included: percentage of patients achieving LDL-C goals
(NCEP ATP III goal of < 100 mg/dL [2.6 mmol/L] and the
2003 European goal of < 2.5 mmol/L [100 mg/dL] for
patients with atherosclerotic disease, type 2 diabetes, or at
high risk of cardiovascular events, as assessed by a System-
atic COronary Risk Evaluation [SCORE] risk ≥ 5% or < 3.0
mmol/L [115 mg/dL] for all other patients), the NCEP
ATP III nonHDL-C goal (< 130 mg/dL [3.4 mmol/L]) and
the combined 2003 European LDL-C and total cholesterol
(TC) goals (LDL-C as stated previously and TC < 4.5 or 5.0
mmol/L [175 or 190 mg/dL] depending on risk category)
at week 6[5,6]; and percentage change from baseline in
HDL-C, TC, TG, nonHDL-C, lipid ratios (LDL-C/HDL-C,
TC/HDL-C, and nonHDL-C/HDL-C), lipoprotein(a) (Lp
[a]), apolipoprotein (Apo)A-I, ApoB, and the ApoB/
ApoA-I ratio at week 6. Cost-effectiveness, frequency and
severity of adverse events (AEs), and the clinical chemistry
data with rosuvastatin 10 mg and atorvastatin 20 mg, were
also assessed.
Assessments
Fasting blood samples were obtained from patients at
week-6 (beginning of dietary lead-in), -2, -1, 0 (randomi-
zation), and week 6, and lipid profiles analyzed at a cen-
tral laboratory (Medical Research Laboratories, KY, USA
for centers in the USA, Mexico, and Australia; Medical
Research Laboratories, Zaventem, Belgium for European
centers). Both laboratories were certified for the standard-
ization of lipid analysis as specified by the Lipid Standard-
ization Program of the Centers for Disease Control and
Prevention, and the National Heart, Lung, and Blood
Institute. Fasting concentrations of LDL-C, HDL-C, TG, TC
and nonHDL-C were determined at weeks -6, -2, -1, 0 and
6, and of ApoA-I, ApoB and Lp(a) at weeks 0 and 6. Fast-
ing LDL-C concentrations were calculated from TC, TG,
and HDL-C using the Friedewald equation in patients
with TG ≤ 4.5 mmol/L (400 mg/dL)[20]. A beta-quantifi-
cation measurement of LDL-C was used when TG > 4.5
mmol/L (400 mg/dL). For the cost-effectiveness analysis,
acquisition costs for rosuvastatin and atorvastatin within
the United Kingdom and the United States were collected
outside the study from pre-specified sources. US costs
were the wholesale acquisition costs as reported by Medi-
Span as of 6 September 2006, and UK costs were taken
from the British National Formulary September 2006.
Blood samples for clinical chemistry, including ALT, CK,
and serum creatinine, were collected at weeks -1, 0, and 6,
and AEs were recorded at weeks -2, -1, 0, and 6 by means
of the standard investigator question "Have you had any
health problems since the previous visit?". Patients were
asked to provide a description of the event, the dates of
onset and resolution, and to assess whether the AE was of
mild, moderate or severe intensity. Urine samples were
collected at weeks 0 and 6 for a dipstick test to measure
urinary protein and blood. Study compliance was
assessed at week 6 by counting returned capsules; patients
were compliant if ≥ 80% of the prescribed medication was
taken.
Statistical analyses
To enable detection of a difference of 3% in mean percent-
age change in LDL-C between the rosuvastatin 10 mg and
atorvastatin 20 mg groups with 90% power at a 5% signif-
icance level, it was estimated that 920 patients would need
to be randomized using a ratio of 1:1. Allowing for an 8%
withdrawal rate during the study, it was planned to rand-
omize 1000 patients. Efficacy analyses included all
patients who had a baseline lipid measurement and at
least 1 post-baseline lipid measurement (intention-to-
treat [ITT] population). The primary analysis used the last
observation carried forward on the ITT population for
patients with missing data. The ITT population was ana-
lyzed by treatment randomly allocated. Percentage
changes from baseline in lipid levels at week 6 were com-
pared by an analysis of variance with terms fitted for treat-
ment, grouped centers, and treatment by grouped center.
Goal achievement was analyzed using logistic regression
analyses.Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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Cost-effectiveness was expressed as cost per patient
achieving their NCEP ATP III or 2003 European LDL-C
goals, and cost per 1% reduction in LDL-C, where costs
consisted of drug acquisition costs alone. The level of effi-
cacy achieved with 6 weeks of treatment was used to esti-
mate the reduction that might be achieved with 1 year of
continued treatment, assuming that compliance and effi-
cacy were maintained. The analysis was carried out within
both a US and a UK setting.
The safety population included all randomized patients
who took at least 1 dose of study medication. No formal
analysis of statistical significance was performed for the
safety and tolerability data.
Results
Study population
Figure 1 presents the patient populations within the study
and reasons for non-eligibility and discontinuations. A
total of 2897 patients were enrolled in the dietary lead-in,
of whom 996 were randomized to treatment (504 to rosu-
vastatin 10 mg, 492 to atorvastatin 20 mg); 954 patients
completed the study (rosuvastatin 10 mg, n = 483; atorv-
astatin 20 mg, n = 471) (Figure 1). One patient was rand-
omized to atorvastatin 20 mg and inadvertently received
rosuvastatin 10 mg for the entire 6-week treatment period.
As a result, the safety population comprised 505 patients
in the rosuvastatin 10 mg group and 491 in the atorvasta-
tin 20 mg group. In each treatment group, 11 patients had
no post-treatment LDL-C value and therefore the ITT pop-
ulation was 493 for rosuvastatin 10 mg and 481 for ator-
vastatin 20 mg.
Baseline demographic characteristics and lipid and lipo-
protein levels were similar in both treatment groups
(Table 1, Table 2). More than 80% of patients had docu-
mented CHD or a CHD-risk equivalent (85.5% for rosuv-
astatin 10 mg, 82.7% for atorvastatin 20 mg). Of those
patients without CHD or a CHD-risk equivalent, 39.5%
had a Framingham 10-year risk of > 20% (Table 1).
On completion of the study, 90.1% of patients in the
rosuvastatin 10 mg group and 89.6% of patients in the




Rosuvastatin 10 mg was significantly more effective at
reducing the primary efficacy variable, LDL-C level, than
atorvastatin 20 mg after 6 weeks of treatment (mean
change -44.6% vs. -42.7%, p < 0.05) (Table 2).
Lipid goals – LDL-C
In terms of secondary efficacy variables, rosuvastatin 10
mg enabled more patients to achieve both the NCEP ATP
III and the 2003 European LDL-C goals than atorvastatin
20 mg (68.8% vs. 62.5%, p < 0.05; 68.0% vs. 63.3%, p <
0.05, respectively). Furthermore, the 2003 European LDL-
C goal was achieved by 65.6% of patients at greatest risk
(established CVD, type 2 diabetes, LDL-C ≥ 6 mmol/L, TC
≥ 8 mmol/L or blood pressure ≥ 180/110 mmHg) receiv-
ing rosuvastatin 10 mg and by 60.3% of at greatest-risk
patients receiving atorvastatin 20 mg.
Lipid goals – nonHDL-C and combined goals
The NCEP ATP III nonHDL-C goal of < 130 mg/dL (3.4
mmol/L) was achieved by 69.7% of patients receiving
rosuvastatin 10 mg and 65.0% of patients receiving atorv-
astatin 20 mg (p = ns). In patients with TG ≥ 2.3 mmol/L
(200 mg/dL) (n = 292), 62.1% of those receiving rosuvas-
tatin 10 mg achieved the combined NCEP ATP III LDL-C
and nonHDL-C goals at week 6, compared with 55.8% of
those receiving atorvastatin 20 mg. The proportion of
patients achieving combined 2003 European LDL-C and
TC goals was 55.2% for rosuvastatin 10 mg and 53.3% for
atorvastatin 20 mg (p = ns).
Improvements across the lipid profile
Rosuvastatin 10 mg increased HDL-C levels to a signifi-
cantly greater extent than atorvastatin 20 mg (mean
change 6.4% and 3.1%, p < 0.001), while similar reduc-
tions in TC, TG, and nonHDL-C levels were observed with
both treatments (Table 2). Ratios of LDL-C/HDL-C, TC/
HDL-C, and nonHDL-C/HDL-C were all reduced to a sig-
nificantly greater extent with rosuvastatin 10 mg than
with atorvastatin 20 mg (p < 0.001, p < 0.01, p < 0.001,
respectively) (Table 2). Lp(a) was increased by 2.1% for
rosuvastatin 10 mg and 13.3% for atorvastatin 20 mg (p <
0.05). Greater improvements in ApoA-I and the ApoB/
ApoA-I ratio were also seen in the rosuvastatin 10 mg
group compared with the atorvastatin 20 mg group (p <
0.001, p = 0.001, respectively), while reductions in ApoB
were similar between treatments (Table 2).
Cost-effectiveness
The yearly acquisition costs were lower for rosuvastatin 10
mg compared with atorvastatin 20 mg in both the US
($959.95 vs. $1204.50) and the UK (£235.03 vs.
£321.20). Furthermore, rosuvastatin 10 mg is more effec-
tive at a lower cost than atorvastatin 20 mg both in terms
of LDL-C reduction and patients achieving NCEP ATP III
or 2003 European LDL-C goals.
Safety and tolerability
Both treatments were well tolerated and the overall fre-
quency and type of AEs were similar between treatment
groups (Table 3). An AE was experienced by 27.5%Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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patients receiving rosuvastatin 10 mg and 26.1% of those
receiving atorvastatin 20 mg; most were of mild-to-mod-
erate intensity (94.2% and 96.1%, respectively) and a
small number were classified as severe (5.8% and 3.9%,
respectively). Myalgia and urinary tract infections were the
most frequently reported AEs in both treatment groups
(Table 3). The other most frequently reported AEs
included headaches and nausea.
Patient populations Figure 1
Patient populations. aOne patient randomized to atorvastatin 20 mg received rosuvastatin 10 mg. bBased on intention-to-
treat populations (n = 504 for rosuvastatin 10 mg; n = 492 for atorvastatin 20 mg).Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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A small number of patients discontinued treatment as a
result of an AE or a drug-related AE (2.8% and 2.4% for
rosuvastatin 10 mg, 2.2% and 2.0% for atorvastatin 20
mg). The most common reported AEs leading to discon-
tinuation (occurring in > 1 patient in either treatment
group) were myalgia, asthenia, bone pain, headache, and
muscular weakness. Few SAEs were reported (1.4% for
rosuvastatin 10 mg, 1.2% for atorvastatin 20 mg) and no
drug-related SAEs were recorded with either treatment.
Two deaths occurred during the study (both in the rosuv-
astatin 10 mg group, one resulting from cardiac failure
and one from MI) and neither of these was considered
related to study treatment and both could be expected in
this type of study population.
Of the 24 (4.8%) treatment-emergent myalgia cases in the
rosuvastatin 10 mg group and the 13(2.6%) cases in the
atorvastatin 20 mg group, 13 (2.6%) and 7 (1.4%) were
thought to be treatment-related, and 4 (0.8%) and 1
(0.2%) cases resulted in withdrawal from the study. None
of the 37 patients with reported myalgia had clinically
important elevations in CK levels (> 10 × ULN) or even
CK > 3 × ULN. One additional patient receiving rosuvas-
tatin 10 mg had an increase in CK of > 5 × ULN, but this
was not associated with muscle symptoms and not con-
sidered clinically important. The mean percentage change
in CK from baseline was 18.6% in the rosuvastatin 10 mg
group and 14.9% in the atorvastatin 20 mg group.
Changes from baseline to the end of treatment for all
serum chemistry measurements were small and similar
between the two treatments. Clinically important eleva-
tions in ALT (> 3 × ULN on two consecutive occasions)
were recorded for one patient receiving atorvastatin 20
mg, although this was not considered to be drug-related.
In addition, no patients showed an increase in serum cre-
atinine > 50% from baseline and > ULN with either treat-
ment.
There were no clinically important abnormalities in uri-
nalysis and no treatment-related trends were reported,
with a low incidence of proteinuria (increase in dipstick-
positive urine protein from "none" or "trace" at baseline
to "≥ ++" at week 6) (0.6% in both groups) and hematuria
(increase in dipstick-positive urine blood from "none" or
"trace" at baseline to "≥ +" at week 6) with rosuvastatin 10
mg and atorvastatin 20 mg (2.6% vs. 2.2%). No cases of
rhabdomyolysis, myopathy, or acute renal failure were
observed.
Table 1: Patient demographics and baseline characteristics (randomized population)
Rosuvastatin 10 mg (n = 504) Atorvastatin 20 mg (n = 492)
Mean age, years (SD) 60.2 (10.4) 60.7 (10.6)
Male gender, n (%) 273 (54.2) 285 (57.9)
Mean BMI, kg/m2 (SD) 29.7 (5.6) 29.7 (5.9)
Race, n (%)
Caucasian 376 (74.6) 380 (77.2)
Hispanic 98 (19.4) 90 (18.3)
Black 23 (4.6) 17 (3.5)
Asian 6 (1.2) 3 (0.6)
Other 1 (0.2) 2 (0.4)
Renal function*, n (%)
Normal 292 (57.9) 271 (55.1)
Mild impairment 177 (35.1) 190 (38.6)
Moderate impairment 35 (6.9) 29 (5.9)
Metabolic syndrome†, n (%) 254 (50.4) 237 (48.2)
Diabetes (type 1 or 2), n (%) 256 (50.8) 250 (50.8)
CHD or CHD-risk equivalents, n (%) 431 (85.5) 407 (82.7)
Patients without CHD or a CHD-risk 
equivalent, n (%)
72 (14.3) 85 (17.3)
Framingham 10-year risk > 20% 30 (6.0) 32 (6.5)
Framingham 10-year risk ≥ 10% and ≤ 20% 17 (3.4) 25 (5.1)
Framingham 10-year risk < 10% 25 (5.0) 28 (5.7)
SD, standard deviation; BMI, body mass index; CHD, coronary heart disease; NCEP ATP, National Cholesterol Education Program Adult 
Treatment Panel; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
*Renal function assessed using creatinine clearance as follows: > 80 mL/min (normal), 50 to ≤ 80 mL/min (mild impairment), 30 to < 50 mL/min 
(moderate impairment). Creatinine clearance was calculated from serum creatinine using the following equations: creatinine clearance (mL/min) = 
([140-age at visit 4] × weight at visit 1 [kg])/72 × serum creatinine at visit 4 (mmol/L) × 0.01131 if male; or creatinine clearance (mL/min) = ([140-
age at visit 4] × weight at visit 1 [kg])/85 × serum creatinine at visit 4 (mmol/L) × 0.01131 if female.
†Modified NCEP ATP III definition [6]: Patients fulfill at least 3 of the following 5 criteria: fasting blood glucose ≥ 6.1 and ≤ 6.9 mmol/L (110 and 125 
mg/dL); waist circumference > 102 cm (male) or > 88 cm (female); TG ≥ 1.7 mmol/L (150 mg/dL); HDL-C < 1.0 mmol/L (40 mg/dL) in men or < 1.3 
mmol/L (50 mg/dL) in women; and hypertension (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg) or taking antihypertensive medication.Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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Discussion
Although a number of previous studies have compared
atorvastatin with rosuvastatin in patients with hypercho-
lesterolemia, some did not include high-risk patients,
some were local studies conducted in a single country,
and many were not powered to study efficacy in terms of
LDL-C lowering [21-24]. PULSAR is the first, prospective,
large-scale, multinational study designed to compare low
doses of rosuvastatin and atorvastatin for their LDL-C-
lowering efficacy in high-risk patients. The PULSAR study
is part of a wider program investigating the efficacy and
safety of rosuvastatin[25]. The program was designed to
address the hypothesis that the statin with the greatest
efficacy for improving the atherogenic lipid profile and
beneficially modifying inflammatory markers will also
slow progression of atherosclerotic plaques, and conse-
quently, result in the greatest reductions in cardiovascular
morbidity and mortality[25]. PULSAR is one of the stud-
ies designed to address the first part of the hypothesis,
investigating the effects of rosuvastatin on the lipid pro-
file. The results of the PULSAR study demonstrate that
rosuvastatin 10 mg was significantly more effective than
atorvastatin 20 mg at reducing LDL-C levels in high-risk
patients with hypercholesterolemia.
This is consistent with findings from previous studies that
have compared rosuvastatin 10 mg and atorvastatin 20
mg in patients with hypercholesterolemia. In three sepa-
rate studies, one with 2431 patients with hypercholester-
olemia (LDL-C ≥ 160 and < 250 mg/dL [4.1 and 6.5
mmol/L]), one with 461 patients (aged 40–80 years) with
CHD and low HDL-C, and one with 263 patients with
type 2 diabetes, rosuvastatin 10 mg was more effective at
reducing LDL-C than atorvastatin 20 mg after 6 weeks of
Table 3: Most frequent (≥ 1.0%) treatment-emergent adverse events (randomized safety population) from the open-label PULSAR 
trial
Number (%) of patients with adverse events
Rosuvastatin 10 mg (n = 505) Atorvastatin 20 mg (n = 491)
Any adverse event 139 (27.5) 128 (26.1)
Myalgia 24 (4.8) 13 (2.6)
Urinary tract infection 13 (2.6) 16 (3.3)
Headache 8 (1.6) 7 (1.4)
Nausea 4 (0.8) 9 (1.8)
Bone pain 8 (1.6) 3 (0.6)
Muscle cramp 5 (1.0) 3 (0.6)
Peripheral edema 3 (0.6) 5 (1.0)
Table 2: Change from baseline in lipoprotein and lipid levels after 6 weeks of treatment (ITT population)
Lipids/lipoproteins Rosuvastatin 10 mg (n = 493) Atorvastatin 20 mg (n = 481) p value*
Mean baseline level, mg/
dL
LSM percentage change 
(SE)
Mean baseline level, mg/
dL
LSM percentage change 
(SE)
LDL-C 165.1 -44.6 (0.6) 164.9 -42.7 (0.6) < 0.05
TC 250.9 -30.8 (0.5) 250.9 -30.7 (0.5) ns
HDL-C 50.3 6.4 (0.5) 49.9 3.1 (0.5) < 0.001
TG 178.1 -17.9 (1.2) 180.3 -19.1 (1.2) ns
NonHDL-C 200.6 -40.1 (0.6) 200.9 -38.9 (0.6) ns
LDL-C/HDL-C 3.5 -47.6 (0.7) 3.5 -44.0 (0.7) < 0.001
TC/HDL-C 5.3 -34.6 (0.5) 5.3 -32.3 (0.5) < 0.01
NonHDL-C/HDL-C 4.3 -43.3 (0.6) 4.3 -40.2 (0.7) < 0.001
Lp(a) 32.6 2.1 (3.8) 27.0 13.3 (3.8) < 0.05
ApoB 157.4 -35.2 (0.6) 156.6 -34.1 (0.6) ns
ApoA-I 160.5 4.8 (0.5) 159.6 1.7 (0.5) < 0.001
ApoB/ApoA-I 1.0 -37.6 (0.7) 1.0 -34.6 (0.7) 0.001
ITT, intention to treat; LSM, least-squares mean; SE, standard error of the mean; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; 
HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Lp, lipoprotein; Apo, apolipoprotein.
To convert cholesterol inmg/dL tommol/L, multiply by .02586; to convert TG in mg/dL to mmol/L, multiply by .01129.
*p value obtained from analysis of variance comparing rosuvastatin 10 mg with atorvastatin for LSM percentage change in lipid and lipoproteins.Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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treatment (45.8% vs. 42.6%, 44.0% vs. 38.4%, 45.9% vs.
41.3%, respectively; all p < 0.05)[11,26,27]. Furthermore,
in an 8-week study of 3140 high-risk patients with hyper-
cholesterolemia and CHD, atherosclerosis, type 2 diabe-
tes, or a 10-year CHD risk > 20%, rosuvastatin 10 mg was
also significantly more efficacious than atorvastatin 20 mg
at reducing LDL-C (47.0% vs. 43.7%, p < 0.001)[12].
Consistent with the greater LDL-C-lowering efficacy in the
PULSAR study, more patients treated with rosuvastatin 10
mg achieved recommended 2003 European and NCEP
ATP III LDL-C goals than with atorvastatin 20 mg. Further-
more, a greater proportion of patients at highest risk (with
established CVD, type 2 diabetes, LDL-C ≥ 6 mmol/L, TC
≥ 8 mmol/L, or blood pressure ≥ 180/110 mmHg)
achieved the more stringent European LDL-C goal of < 2.5
mmol/L (100 mg/dL) with rosuvastatin 10 mg than with
atorvastatin 20 mg. A previous study of 2829 high-risk
patients showed that 52% did not achieve a LDL-C goal of
< 2.5 mmol/L (100 mg/dL) with the initial statin dose[9].
Of the remaining patients, 55% did not have their dosage
up-titrated, and of those whose treatment was titrated to a
higher dose, only 31% achieved the LDL-C goal. There-
fore, selecting a statin that is more efficacious at starting
dose will reduce the need for dose titration and improve
goal achievement, potentially leading to benefits in CVD-
risk reduction.
HDL-C is thought to have a protective role against the
development of atherosclerotic plaques[28] and a low
HDL-C level is considered a risk factor for CHD. Agents
that improve HDL-C as well as lower LDL-C may offer
additional benefits for CHD-risk reduction. In the present
study, increases in HDL-C were significantly greater with
rosuvastatin 10 mg than with atorvastatin 20 mg.
Several studies have shown that other lipid parameters,
such as apolipoproteins and lipid ratios, are better predic-
tors of CVD risk than LDL-C and may be used to guide
therapeutic decisions[29]. For example, in the AMORIS
study of 175,553 individuals, ApoB was found to be a
stronger predictor than LDL-C for risk of fatal MI[30]. Fur-
thermore, the ApoB/ApoA-I ratio was found to be the
most effective predictor of MI in the INTERHEART study
of 15,152 patients with CHD from 52 countries[31]. In
the present study, patients receiving rosuvastatin 10 mg
also showed greater improvements in levels of ApoA-I,
and ratios of LDL-C/HDL-C, TC/LDL-C, nonHDL-C/
HDL-C, and ApoB/ApoA-I, compared with those receiving
atorvastatin 20 mg. Reductions in TC, TG, nonHDL-C,
and ApoB levels were similar between treatments. Thus,
the results of the PULSAR study are consistent with those
from previous studies comparing the effects of rosuvasta-
tin 10 mg and atorvastatin 20 mg on lipid parameters.
Rosuvastatin 10 mg significantly improved levels of HDL-
C, TC, and nonHDL-C and ratios of LDL-C/HDL-C and
TC/HDL-C, compared with atorvastatin 20 mg in previous
studies with high-risk patients[12,26,27]. Improvements
in the atherogenic lipid profile may be beneficial for
reducing global risk in patients with CHD[6]. Further-
more, as part of the wider rosuvastatin clinical trial pro-
gram, one study has reported that rosuvastatin 40 mg can
arrest and even reverse progression of atherosclerosis, in
association with reductions in LDL-C[32]. Ultimately, to
assure the clinical relevance of changes in the lipid profile,
the greater efficacy of rosuvastatin in terms of LDL-C low-
ering must translate into reductions in morbidity and
mortality. As such, several outcomes studies are now
underway to assess the efficacy of rosuvastatin in high-risk
patients [33-35].
Results of the PULSAR study showed rosuvastatin 10 mg
to be a cost-effective alternative to atorvastatin 20 mg,
both in terms of cost per percentage LDL-C reduction and
cost per patient achieving their NCEP ATP III or 2003
European LDL-C goal, both in a UK and US setting. These
results are in line with several previous cost-effectiveness
analyses, which reported rosuvastatin to be more cost-
effective than atorvastatin, pravastatin and simvastatin
[36-38]. A recent UK study showed simvastatin 40 mg to
be a cost-effective alternative to atorvastatin 20 mg, and
has stressed the importance of comparing costs when con-
sidering statin therapies[39]. The study reported the ben-
efits of switching to more cost-effective statins in terms of
potential savings to the health service[39]. Further eco-
nomic analyses of rosuvastatin are now needed to deter-
mine its potential as a more cost-effective therapy
compared with other statins.
Both rosuvastatin and atorvastatin were well tolerated in
this study, and none of the reported AEs were unexpected
given the age and underlying medical conditions of the
patient population. Most AEs were of mild or moderate
severity, and were not considered to be treatment-related.
The most commonly reported AE was myalgia, although
none of the cases were associated with a clinically impor-
tant elevation in CK (> 10 × ULN) (or even a CK > 3 ×
ULN). Furthermore, there were no reports of rhabdomy-
olysis, renal, or liver insufficiencies during the study. It is
possible that the open-label design of the study could
potentially have biased reporting of AEs, especially since
the study was conducted at a time of high media activity
related to rosuvastatin. This is supported by an NLA anal-
ysis of AE reporting rates of several statins, which found
that the reporting of rosuvastatin-associated rhabdomyol-
ysis and renal failure increased following media public-
ity[19]. However, the AE reporting patterns of
rosuvastatin did not differ greatly from those of other stat-
ins, once differential reporting effects were taken into
account.Trials 2006, 7:35 http://www.trialsjournal.com/content/7/1/35
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Results from the PULSAR study are consistent with previ-
ous studies, which have assessed the safety of rosuvastatin
and atorvastatin in a range of patients with dyslipi-
demia[16,40]. In a global analysis of 12,400 patients in
the rosuvastatin phase II/III clinical program, Shepherd et
al[16] found that rosuvastatin 5–40 mg had a similar
safety profile to other statins, and demonstrated a favora-
ble benefit-risk profile across this dose range. Neverthe-
less, there has been some concern regarding the potential
toxicity of rosuvastatin, particularly in terms of renal and
muscle events [41]. However, the Food and Drug Admin-
istration recently conducted a comprehensive review of
available safety data from pre-clinical studies, pre-market-
ing clinical trials, phase IV studies and post-marketing AE
reports [42]. The review concluded that rosuvastatin poses
no greater risk of muscle toxicity or serious renal injury
compared with other statins [42]. Furthermore, a pooled
data analysis of 9416 patients in 44 clinical trials found
that the safety of atorvastatin 10–80 mg was also similar
to that of other statins[40]. Results from 2 recent large-
scale, independent, pharmacoepidemiologic studies con-
ducted in The Netherlands and the USA were in accord-
ance with these findings [17,18]. These studies of real-
world patient data in over 96,000 patients receiving statin
therapy found that the incidence of pre-defined events
requiring hospitalization associated with the muscle, liver
or kidneys was the same for all currently marketed statins
[17,18].
Conclusion
In conclusion, at recommended starting doses, rosuvasta-
tin (10 mg) was more efficacious than atorvastatin (20
mg), in terms of LDL-C lowering, LDL-C goal achieve-
ment, and improving the atherogenic lipid profile. The
greater efficacy of rosuvastatin at starting dose should help
to reduce the need for dose titration and enable more
patients to achieve recommended treatment goals in clin-
ical practice. In addition, improvements across the whole
atherogenic lipid profile, including increases in HDL-C,
may provide further reductions in the risk of CVD.
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